(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
Investigating the Advantages of a Bank account: A Complete Aide- Firefighters rescue two Israelis trapped in vehicles on flooded roads in West Bank
- Understanding the Rudiments of Tree Administrations
- Instructions to Pick the Right Tires for Your Slam 1500.
- Discovering a true sense of harmony: Contemplation and Care Practices
- Fact Check: Israeli Channel 13, Al Jazeera Did NOT Confirm Hezbollah Captured All Or Part Of Kiryat Shmona
- If evolution is real, then why isn’t it happening now? An anthropologist explains that humans actually are still evolving
- Day to day Temporary Positions That Compensate Fairly in the US
- The German series proving subtitles can be sexy — and wildly addictive
